相似文献
1
Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
Br J Cancer. 1980 Oct;42(4):510-5. doi: 10.1038/bjc.1980.273.
2
Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.
Br J Cancer. 1983 Jan;47(1):111-4. doi: 10.1038/bjc.1983.13.
3
[Value of the determination of beta-2-microglobulin in the monitoring of myeloma. Apropos of 290 determinations].
Rev Rhum Mal Osteoartic. 1982 Apr;49(5):359-63.
4
[Serum ferritin and beta-2-microglobulin in multiple myeloma].
Acta Med Austriaca. 1982;9(5-6):227-31.
5
Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.
Br J Haematol. 1990 Aug;75(4):506-10. doi: 10.1111/j.1365-2141.1990.tb07790.x.
6
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
Br J Cancer. 1985 Jul;52(1):1-6. doi: 10.1038/bjc.1985.140.
7
Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
Cancer Detect Prev. 1983;6(1-2):297-301.
8
Urinary excretion of beta 2-microglobulin in myeloma patients.
Clin Chim Acta. 1980 Dec 22;108(3):369-74. doi: 10.1016/0009-8981(80)90343-5.
9
Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.
Eur J Cancer Clin Oncol. 1983 Oct;19(10):1361-4. doi: 10.1016/0277-5379(93)90004-o.
10
[Serum beta-2-microglobulin in multiple myeloma. Practical value].
Rev Rhum Mal Osteoartic. 1981 Mar;48(3):235-40.
引用本文的文献
1
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
Front Oncol. 2022 Feb 8;12:820768. doi: 10.3389/fonc.2022.820768. eCollection 2022.
2
A Study on Free Light Chain Assay and Serum Immunofixation Electrophoresis for the Diagnosis of Monoclonal Gammopathies.
Indian J Clin Biochem. 2019 Jan;34(1):76-81. doi: 10.1007/s12291-017-0718-6. Epub 2017 Nov 29.
3
Detection and identification of serum monoclonal immunoglobulin by immunoisoelectric focusing. Limits of sensitivity and use during relapse of multiple myeloma.
J Clin Pathol. 1984 Mar;37(3):255-62. doi: 10.1136/jcp.37.3.255.
4
Evaluation of serum beta 2-microglobulin as a prognostic indicator in myelomatosis.
Br J Cancer. 1983 Jan;47(1):111-4. doi: 10.1038/bjc.1983.13.
5
Beta 2-microglobulin in haematological malignancies.
Br Med J (Clin Res Ed). 1981 Mar 28;282(6269):1013. doi: 10.1136/bmj.282.6269.1013.
6
The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis.
Br J Cancer. 1985 Jul;52(1):1-6. doi: 10.1038/bjc.1985.140.
7
Changes in plasma beta 2 microglobulin concentrations after allogeneic bone marrow transplantation.
J Clin Pathol. 1987 Jun;40(6):657-62. doi: 10.1136/jcp.40.6.657.
8
Expression of beta-2-microglobulin by nasopharyngeal carcinoma.
Br J Cancer. 1992 Sep;66(3):555-7. doi: 10.1038/bjc.1992.313.
本文引用的文献
1
Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane.
Proc Natl Acad Sci U S A. 1974 May;71(5):2123-7. doi: 10.1073/pnas.71.5.2123.
2
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
Cancer. 1975 Sep;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u.
3
Prognostic factors in multiple myeloma.
Cancer. 1975 Oct;36(4):1192-201. doi: 10.1002/1097-0142(197510)36:4<1192::aid-cncr2820360403>3.0.co;2-i.
4
Clinical staging in multiple myeloma.
Br J Haematol. 1979 Jun;42(2):199-205. doi: 10.1111/j.1365-2141.1979.tb01124.x.
5
[beta2-Microglobulin and monoclonal gammapathies (author's transl)].
Pathol Biol (Paris). 1978 Sep;26(6):348-50.
6
beta 2-microglogulin levels in cancerous and other disease states.
Clin Chim Acta. 1976 Mar 15;67(3):307-13. doi: 10.1016/0009-8981(76)90339-9.
7
Renal function in patients with multiple myeloma.
Medicine (Baltimore). 1978 Mar;57(2):151-66. doi: 10.1097/00005792-197803000-00003.
Zotero 插件